Results 161 to 170 of about 26,004 (264)

Symptom Clusters and Symptom Burden in Cancer Survivors

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Context Limited information is available on the symptom burden and symptom clusters in cancer survivors. Objectives Describe the occurrence, severity, and distress of 44 symptoms; determine risk factors associated with a higher symptom burden; and evaluate for symptom clusters using symptom occurrence rates.
Marilyn J. Hammer, Carolyn Harris, Rachel Pozzar, Karin Snowberg, Steven M. Paul, Bruce A. Cooper, Maura E. Abbott, Susan Chang, Stacey Kenfield, Erin Van Blarigan, Katherine Van Loon, Jon D. Levine, Christine Miaskowski   +12 more
wiley   +1 more source

Targeting Autophagy in Ovarian Cancer: The Emerging Role of Ginsenosides

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Background Ovarian cancer, the third most prevalent gynecological malignancy, is frequently diagnosed at an advanced stage owing to its asymptomatic early progression. Despite the application of conventional therapies, clinical management remains limited by adverse effects and the development of drug resistance.
Yuxin Guo, Cuilan Yun, Yuemei Zhang, Xu Yang, Huiqin Liu   +4 more
wiley   +1 more source

Primary Pericardial Angiosarcoma Demonstrating Initial Response Followed by Progression on First‐Line Chemotherapy: A Case Report

Clinical Case Reports, Volume 14, Issue 3, March 2026.
ABSTRACT Primary pericardial angiosarcoma is an exceedingly rare and highly aggressive malignancy arising from pericardial endothelial cells, with a reported median survival of approximately 7 months. Owing to its non‐specific clinical presentation, diagnosis is frequently delayed, particularly in tuberculosis‐endemic regions, where symptoms may be ...
Ujjwal Kumar Thakur, Akash Subedi, Rheecha Joshi, Sunita Dhanchha, Sumit Yadav, Binaya Pangyani, Ajaya Acharya, Punam KC, Sunil Shrestha, Gerim Prasai, Abish Adhikari, Anjani Kumar Jha, Subhas Pandit, Simit Sapkota   +13 more
wiley   +1 more source

NSCLC: Verträglichere Therapie mit nab-Paclitaxel [PDF]

Im Focus Onkologie, 2015
openaire   +1 more source

Nab-paclitaxel versus paclitaxel for taxane acute pain syndrome in solid tumors: a systematic review and meta-analysis. [PDF]

Front Oncol
Wei L, Li H, Wang Z.
europepmc   +1 more source

Neoadjuvant nab-paclitaxel in the treatment of breast cancer [PDF]

, 2016
Eleftherios P. Mamounas, Naoto T. Ueno
core   +1 more source

Thrombotic Thrombocytopenic Purpura in a Patient With Triple‐Negative Breast Cancer Treated With PD‐L1 Inhibition and Taxane Chemotherapy

Clinical Case Reports, Volume 14, Issue 3, March 2026.
PET imaging of a 56 year old woman with HIV and advanced triple negative breast cancer with regional lymph node and bone metastases. ABSTRACT Thrombocytopenic purpura (TTP) is a hematologic emergency that may occur with PD‐L1 immunotherapy. New or worsening anemia and thrombocytopenia in patients started on PD‐L1 inhibitors should raise suspicion for ...
Jason Ke, Albert C. Chong, Robert Hsu, Anastasia Martynova, Noah Wald‐Dickler, Anishka D'Souza, Caroline Piatek, Gino K. In   +7 more
wiley   +1 more source

A Case of Recurrent Acute Pancreatitis After Gemcitabine + Nab-Paclitaxel and Modified FOLFIRINOX Therapy for Advanced Recurrent Pancreatic Cancer. [PDF]

Cureus
Inada Y, Sango H, Kasuga N, Yukawa H, Sano M.   +4 more
europepmc   +1 more source

Denosumab Combined With PARP Inhibitors and Chemoradiotherapy for Treating Triple Negative Breast Cancer With Bone Metastasis: A Case Report

Cancer Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background Triple‐negative breast cancer (TNBC) with bone metastasis is associated with poor prognosis and limited treatment options. Denosumab has shown efficacy in preventing skeletal‐related events, while PARP inhibitors have demonstrated promising activity in patients with homologous recombination deficiency.
Li Liu, Lan Yu, Yu Wang, Hongmei Zhang, Xiaotao Zhang   +4 more
wiley   +1 more source

Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer. [PDF]

Oncologist
Sun L, Gong Z, Wang L, Kuang L, Huang Q, Pei B, Yuan X, Qiu H.   +7 more
europepmc   +1 more source